Core Viewpoint - 康希诺生物's stock surged over 8% following the release of its half-year performance report, indicating positive market sentiment towards the company's financial results and growth prospects [1] Financial Performance - The company reported a revenue of approximately 374 million RMB, representing a year-on-year increase of 31.1% [1] - The net loss attributable to the owners narrowed to 13.485 million RMB, a significant reduction of 94.02% compared to the previous year [1] Product Development - 康希诺生物 continues to advance the commercialization of its meningococcal conjugate vaccine, with successful penetration into the mid-to-high-end vaccine market in China [1] - Sales revenue from the meningococcal conjugate vaccine reached approximately 364 million RMB, marking a year-on-year growth of 38.4%, contributing to the company's stable revenue growth [1]

消息面上，康希诺生物发布上半年业绩，收入约3.74亿元，同比增长31.1%；公司所有者应占期内亏损 1348.5万元，同比收窄94.02%。报告期内，公司继续推进流脑结合疫苗的商业化，截至本报告日期，曼 海欣已成功在中国中高端疫苗市场商业化，且其渗透率持续提升。公司流脑结合疫苗产生销售收入约人 民币3.64亿元，较去年同期增长38.4%，为公司稳定收入增长做出了贡献。 康希诺生物(06185)午前飙升逾8%，截至发稿，涨8.05%，报52.75港元，成交额9546.27万港元。 ...

消息面上，康希诺生物发布上半年业绩，收入约3.74亿元，同比增长31.1%；公司所有者应占期内亏损 1348.5万元，同比收窄94.02%。报告期内，公司继续推进流脑结合疫苗的商业化，截至本报告日期，曼 海欣已成功在中国中高端疫苗市场商业化，且其渗透率持续提升。公司流脑结合疫苗产生销售收入约人 民币3.64亿元，较去年同期增长38.4%，为公司稳定收入增长做出了贡献。 智通财经APP获悉，康希诺生物(06185)午前飙升逾8%，截至发稿，涨8.05%，报52.75港元，成交额 9546.27万港元。 ...